![]() |
|||||||
|
Fusion Protein:TADA2A-MED24 |
Fusion Gene and Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: TADA2A-MED24 | FusionPDB ID: 88692 | FusionGDB2.0 ID: 88692 | Hgene | Tgene | Gene symbol | TADA2A | MED24 | Gene ID | 6871 | 9862 |
Gene name | transcriptional adaptor 2A | mediator complex subunit 24 | |
Synonyms | ADA2|ADA2A|KL04P|TADA2L|hADA2 | ARC100|CRSP100|CRSP4|DRIP100|MED5|THRAP4|TRAP100 | |
Cytomap | 17q12 | 17q21.1 | |
Type of gene | protein-coding | protein-coding | |
Description | transcriptional adapter 2-alphaADA2-like proteintranscriptional adaptor 2 alpha | mediator of RNA polymerase II transcription subunit 24CRSP complex subunit 4activator-recruited cofactor 100 kDa componentcofactor required for Sp1 transcriptional activation subunit 4cofactor required for Sp1 transcriptional activation, subunit 4, 10 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | O75448 Main function of 5'-partner protein: FUNCTION: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. {ECO:0000269|PubMed:12218053, ECO:0000269|PubMed:16595664}. | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000591992, ENST00000225396, ENST00000394395, ENST00000417170, ENST00000586023, | ENST00000394126, ENST00000479829, ENST00000356271, ENST00000394127, ENST00000394128, ENST00000501516, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 17 X 18 X 7=2142 | 16 X 15 X 7=1680 |
# samples | 18 | 23 | |
** MAII score | log2(18/2142*10)=-3.57288966842058 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(23/1680*10)=-2.86875546672175 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Fusion gene context | PubMed: TADA2A [Title/Abstract] AND MED24 [Title/Abstract] AND fusion [Title/Abstract] | ||
Fusion neoantigen context | PubMed: TADA2A [Title/Abstract] AND MED24 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | TADA2A(35818689)-MED24(38192407), # samples:3 | ||
Anticipated loss of major functional domain due to fusion event. | TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF. TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. TADA2A-MED24 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF. TADA2A-MED24 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | TADA2A | GO:0043966 | histone H3 acetylation | 9674425 |
Tgene | MED24 | GO:0006367 | transcription initiation from RNA polymerase II promoter | 12218053 |
Tgene | MED24 | GO:0045893 | positive regulation of transcription, DNA-templated | 10198638 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:35818689/chr17:38192407) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Amino Acid Sequences |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000394395 | TADA2A | chr17 | 35802753 | + | ENST00000394126 | MED24 | chr17 | 38192407 | - | 3893 | 704 | 173 | 3460 | 1095 |
ENST00000586023 | TADA2A | chr17 | 35802753 | + | ENST00000394126 | MED24 | chr17 | 38192407 | - | 3828 | 639 | 108 | 3395 | 1095 |
ENST00000225396 | TADA2A | chr17 | 35802753 | + | ENST00000394126 | MED24 | chr17 | 38192407 | - | 4090 | 901 | 370 | 3657 | 1095 |
ENST00000417170 | TADA2A | chr17 | 35802753 | + | ENST00000394126 | MED24 | chr17 | 38192407 | - | 4089 | 900 | 369 | 3656 | 1095 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000394395 | ENST00000394126 | TADA2A | chr17 | 35802753 | + | MED24 | chr17 | 38192407 | - | 0.00623042 | 0.9937696 |
ENST00000586023 | ENST00000394126 | TADA2A | chr17 | 35802753 | + | MED24 | chr17 | 38192407 | - | 0.006293456 | 0.9937065 |
ENST00000225396 | ENST00000394126 | TADA2A | chr17 | 35802753 | + | MED24 | chr17 | 38192407 | - | 0.007864974 | 0.99213505 |
ENST00000417170 | ENST00000394126 | TADA2A | chr17 | 35802753 | + | MED24 | chr17 | 38192407 | - | 0.00785762 | 0.9921423 |
![]() |
Get the fusion protein sequences from here. |
Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for TADA2A-MED24 |
![]() |
Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
TADA2A | chr17 | 35802753 | MED24 | chr17 | 38192407 | 639 | 177 | MAGYMPARADFIEMVSYSSVLTAISK |
TADA2A | chr17 | 35802753 | MED24 | chr17 | 38192407 | 704 | 177 | MAGYMPARADFIEMVSYSSVLTAISK |
TADA2A | chr17 | 35802753 | MED24 | chr17 | 38192407 | 900 | 177 | MAGYMPARADFIEMVSYSSVLTAISK |
TADA2A | chr17 | 35802753 | MED24 | chr17 | 38192407 | 901 | 177 | MAGYMPARADFIEMVSYSSVLTAISK |
Top |
Potential FusionNeoAntigen Information of TADA2A-MED24 in HLA I |
![]() |
TADA2A-MED24_35802753_38192407.msa |
![]() * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:04 | ARADFIEMV | 0.9995 | 0.7772 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:02 | ARADFIEMV | 0.9995 | 0.5204 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:05 | ARADFIEMV | 0.9994 | 0.7723 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:07 | ARADFIEMV | 0.9994 | 0.6178 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B39:06 | ARADFIEMV | 0.9989 | 0.9046 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B39:24 | ARADFIEMV | 0.9986 | 0.5999 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B38:02 | ARADFIEMV | 0.9966 | 0.9469 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B41:01 | IEMVSYSSV | 0.7633 | 0.9865 | 11 | 20 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B47:01 | ADFIEMVSY | 0.7288 | 0.5151 | 8 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B18:01 | ADFIEMVSY | 0.7033 | 0.8965 | 8 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B50:01 | IEMVSYSSV | 0.6705 | 0.658 | 11 | 20 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B52:01 | IEMVSYSSV | 0.2784 | 0.8245 | 11 | 20 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:01 | MPARADFIEM | 0.9965 | 0.9634 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:08 | MPARADFIEM | 0.991 | 0.9284 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:05 | MPARADFIEM | 0.9907 | 0.8521 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B53:01 | MPARADFIEM | 0.983 | 0.5877 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:03 | MPARADFIEM | 0.9776 | 0.9438 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B15:17 | RADFIEMVSY | 0.9609 | 0.9196 | 7 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:04 | MPARADFIEM | 0.9282 | 0.9798 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:02 | MPARADFIEM | 0.9282 | 0.9798 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:04 | ARADFIEMVSY | 0.9999 | 0.7306 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:05 | ARADFIEMVSY | 0.9999 | 0.7759 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B15:18 | ARADFIEMVSY | 0.9809 | 0.7836 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C05:09 | RADFIEMV | 1 | 0.9595 | 7 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:05 | ARADFIEM | 0.9999 | 0.9645 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C08:15 | RADFIEMV | 0.9999 | 0.968 | 7 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:27 | ARADFIEM | 0.9998 | 0.9575 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:95 | ARADFIEM | 0.9998 | 0.6864 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:67 | ARADFIEM | 0.9994 | 0.968 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:80 | ARADFIEM | 0.9994 | 0.968 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:46 | ARADFIEM | 0.999 | 0.9174 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C12:16 | ARADFIEM | 0.9723 | 0.9723 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B40:06 | IEMVSYSSV | 0.9996 | 0.62 | 11 | 20 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:14 | ARADFIEMV | 0.9995 | 0.7556 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B39:12 | ARADFIEMV | 0.9975 | 0.9094 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:05 | ARADFIEMV | 0.9957 | 0.9687 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B73:01 | ARADFIEMV | 0.9934 | 0.8189 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:27 | ARADFIEMV | 0.987 | 0.9645 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:95 | ARADFIEMV | 0.9839 | 0.7242 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:29 | ARADFIEMV | 0.9825 | 0.9265 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:03 | ARADFIEMV | 0.9749 | 0.7948 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:13 | ARADFIEMV | 0.9655 | 0.9588 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:46 | ARADFIEMV | 0.9103 | 0.9458 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:80 | ARADFIEMV | 0.886 | 0.9757 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:67 | ARADFIEMV | 0.886 | 0.9757 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:19 | ARADFIEMV | 0.8841 | 0.8507 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:10 | ARADFIEMV | 0.8716 | 0.984 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B51:07 | IEMVSYSSV | 0.129 | 0.7558 | 11 | 20 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C12:16 | ARADFIEMV | 0.0075 | 0.9777 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B07:12 | MPARADFIEM | 0.9931 | 0.5441 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B42:02 | MPARADFIEM | 0.9339 | 0.6981 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:12 | MPARADFIEM | 0.9282 | 0.9798 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B42:01 | MPARADFIEM | 0.9278 | 0.6877 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B15:07 | RADFIEMVSY | 0.9252 | 0.8291 | 7 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B39:10 | MPARADFIEM | 0.897 | 0.9046 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:14 | ARADFIEMVSY | 0.9997 | 0.724 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:27 | ARADFIEMVSY | 0.9997 | 0.9517 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:95 | ARADFIEMVSY | 0.9995 | 0.6705 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:05 | ARADFIEMVSY | 0.9995 | 0.9621 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:03 | ARADFIEMVSY | 0.9991 | 0.7991 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:19 | ARADFIEMVSY | 0.9987 | 0.7528 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:80 | ARADFIEMVSY | 0.9981 | 0.9558 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:67 | ARADFIEMVSY | 0.9981 | 0.9558 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:46 | ARADFIEMVSY | 0.9972 | 0.9162 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:10 | ARADFIEMVSY | 0.9958 | 0.9712 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C01:30 | YMPARADFIEM | 0.9882 | 0.9614 | 3 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C12:16 | ARADFIEMVSY | 0.9405 | 0.9586 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C05:01 | RADFIEMV | 1 | 0.9595 | 7 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:01 | ARADFIEM | 0.9999 | 0.6724 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C08:02 | RADFIEMV | 0.9999 | 0.968 | 7 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:22 | ARADFIEM | 0.9996 | 0.7259 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C06:08 | ARADFIEM | 0.9996 | 0.9958 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:17 | ARADFIEM | 0.9996 | 0.9725 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:02 | ARADFIEM | 0.9994 | 0.968 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B18:04 | DFIEMVSY | 0.9776 | 0.8635 | 9 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B18:07 | DFIEMVSY | 0.9691 | 0.814 | 9 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C06:17 | ARADFIEM | 0.9631 | 0.9954 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C06:02 | ARADFIEM | 0.9631 | 0.9954 | 6 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:09 | ARADFIEMV | 0.9996 | 0.7541 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:06 | ARADFIEMV | 0.9995 | 0.8116 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:10 | ARADFIEMV | 0.9995 | 0.8812 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:08 | ARADFIEMV | 0.9994 | 0.6782 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B39:31 | ARADFIEMV | 0.9979 | 0.9072 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:01 | ARADFIEMV | 0.9834 | 0.7256 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:17 | ARADFIEMV | 0.978 | 0.9767 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C06:08 | ARADFIEMV | 0.9479 | 0.9961 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:02 | ARADFIEMV | 0.886 | 0.9757 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B18:04 | ADFIEMVSY | 0.867 | 0.9073 | 8 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B18:11 | ADFIEMVSY | 0.8374 | 0.8667 | 8 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:04 | ARADFIEMV | 0.7992 | 0.9481 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:28 | ADFIEMVSY | 0.7788 | 0.8942 | 8 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B41:03 | IEMVSYSSV | 0.7475 | 0.7612 | 11 | 20 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B18:08 | ADFIEMVSY | 0.7212 | 0.7002 | 8 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B18:05 | ADFIEMVSY | 0.7033 | 0.8965 | 8 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C06:06 | ARADFIEMV | 0.6993 | 0.9932 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B18:06 | ADFIEMVSY | 0.6905 | 0.8953 | 8 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B50:04 | IEMVSYSSV | 0.6705 | 0.658 | 11 | 20 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B50:05 | IEMVSYSSV | 0.6705 | 0.658 | 11 | 20 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:22 | ARADFIEMV | 0.5998 | 0.7596 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C06:02 | ARADFIEMV | 0.04 | 0.9965 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C06:17 | ARADFIEMV | 0.04 | 0.9965 | 6 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:23 | MPARADFIEM | 0.9965 | 0.9648 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:77 | MPARADFIEM | 0.9965 | 0.9634 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:30 | MPARADFIEM | 0.991 | 0.9398 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:17 | MPARADFIEM | 0.991 | 0.9398 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:11 | MPARADFIEM | 0.9823 | 0.9717 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:13 | MPARADFIEM | 0.9761 | 0.9473 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:24 | MPARADFIEM | 0.9666 | 0.9331 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:09 | MPARADFIEM | 0.9282 | 0.9798 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B15:35 | RADFIEMVSY | 0.9102 | 0.9412 | 7 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B67:01 | MPARADFIEM | 0.9084 | 0.8231 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B15:08 | MPARADFIEM | 0.8575 | 0.954 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B15:11 | MPARADFIEM | 0.8571 | 0.9554 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B35:43 | MPARADFIEM | 0.8531 | 0.9567 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B56:05 | MPARADFIEM | 0.7441 | 0.5275 | 4 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:08 | ARADFIEMVSY | 0.9999 | 0.6693 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:10 | ARADFIEMVSY | 0.9999 | 0.8381 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:01 | ARADFIEMVSY | 0.9996 | 0.651 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B27:09 | ARADFIEMVSY | 0.9993 | 0.7473 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:22 | ARADFIEMVSY | 0.9981 | 0.7424 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:02 | ARADFIEMVSY | 0.9981 | 0.9558 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C07:17 | ARADFIEMVSY | 0.9968 | 0.9597 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-C01:02 | YMPARADFIEM | 0.9894 | 0.9318 | 3 | 14 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B15:54 | ARADFIEMVSY | 0.9426 | 0.8803 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B15:68 | ARADFIEMVSY | 0.9316 | 0.7368 | 6 | 17 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | HLA-B51:09 | MPARADFIEMV | 0.8769 | 0.5691 | 4 | 15 |
Top |
Potential FusionNeoAntigen Information of TADA2A-MED24 in HLA II |
![]() |
TADA2A-MED24_35802753_38192407.msa |
![]() * We used NetMHCIIpan v4.1 (%rank<0.5). |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | DRB1-0901 | MAGYMPARADFIEMV | 0 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | DRB1-0904 | MAGYMPARADFIEMV | 0 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | DRB1-0905 | MAGYMPARADFIEMV | 0 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | DRB1-0907 | MAGYMPARADFIEMV | 0 | 15 |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 | DRB1-0909 | MAGYMPARADFIEMV | 0 | 15 |
Top |
Fusion breakpoint peptide structures of TADA2A-MED24 |
![]() * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
537 | ARADFIEMVSYSSV | TADA2A | MED24 | chr17 | 35802753 | chr17 | 38192407 | 901 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TADA2A-MED24 |
![]() * We used Glide to predict the interaction between HLAs and neoantigens. |
HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
HLA-B14:02 | 3BVN | 537 | ARADFIEMVSYSSV | -7.9962 | -8.1096 |
HLA-B14:02 | 3BVN | 537 | ARADFIEMVSYSSV | -5.70842 | -6.74372 |
HLA-B52:01 | 3W39 | 537 | ARADFIEMVSYSSV | -6.83737 | -6.95077 |
HLA-B52:01 | 3W39 | 537 | ARADFIEMVSYSSV | -4.4836 | -5.5189 |
HLA-A11:01 | 4UQ2 | 537 | ARADFIEMVSYSSV | -10.0067 | -10.1201 |
HLA-A11:01 | 4UQ2 | 537 | ARADFIEMVSYSSV | -9.03915 | -10.0745 |
HLA-A24:02 | 5HGA | 537 | ARADFIEMVSYSSV | -6.56204 | -6.67544 |
HLA-A24:02 | 5HGA | 537 | ARADFIEMVSYSSV | -5.42271 | -6.45801 |
HLA-B44:05 | 3DX8 | 537 | ARADFIEMVSYSSV | -7.85648 | -8.89178 |
HLA-B44:05 | 3DX8 | 537 | ARADFIEMVSYSSV | -5.3978 | -5.5112 |
HLA-A02:01 | 6TDR | 537 | ARADFIEMVSYSSV | -3.37154 | -4.40684 |
Top |
Vaccine Design for the FusionNeoAntigens of TADA2A-MED24 |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 11 | 20 | IEMVSYSSV | ATTGAGATGGTGTCCTACTCTTCTGTC |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 3 | 14 | YMPARADFIEM | TACATGCCAGCTCGAGCAGATTTCATTGAGATG |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 4 | 14 | MPARADFIEM | ATGCCAGCTCGAGCAGATTTCATTGAGATG |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 4 | 15 | MPARADFIEMV | ATGCCAGCTCGAGCAGATTTCATTGAGATGGTG |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 6 | 14 | ARADFIEM | GCTCGAGCAGATTTCATTGAGATG |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 6 | 15 | ARADFIEMV | GCTCGAGCAGATTTCATTGAGATGGTG |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 6 | 17 | ARADFIEMVSY | GCTCGAGCAGATTTCATTGAGATGGTGTCCTAC |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 7 | 15 | RADFIEMV | CGAGCAGATTTCATTGAGATGGTG |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 7 | 17 | RADFIEMVSY | CGAGCAGATTTCATTGAGATGGTGTCCTAC |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 8 | 17 | ADFIEMVSY | GCAGATTTCATTGAGATGGTGTCCTAC |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 9 | 17 | DFIEMVSY | GATTTCATTGAGATGGTGTCCTAC |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
TADA2A-MED24 | chr17 | 35802753 | chr17 | 38192407 | 0 | 15 | MAGYMPARADFIEMV | ATGGCCGGGTACATGCCAGCTCGAGCAGATTTCATTGAGATGGTG |
Top |
Information of the samples that have these potential fusion neoantigens of TADA2A-MED24 |
![]() |
Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
BRCA | TADA2A-MED24 | chr17 | 35802753 | ENST00000225396 | chr17 | 38192407 | ENST00000394126 | TCGA-AR-A0TQ |
Top |
Potential target of CAR-T therapy development for TADA2A-MED24 |
![]() |
![]() * Minus value of BPloci means that the break point is located before the CDS. |
- In-frame and retained 'Transmembrane'. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
![]() * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to TADA2A-MED24 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to TADA2A-MED24 |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |